These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 33458427)
21. The impact of [ Frenzel T; Tienken M; Abel M; Berliner C; Klutmann S; Beyersdorff D; Schwarz R; Krüll A; Bannas P Strahlenther Onkol; 2018 Jul; 194(7):646-654. PubMed ID: 29572670 [TBL] [Abstract][Full Text] [Related]
22. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515 [TBL] [Abstract][Full Text] [Related]
23. Biodistribution and radiation dosimetry of [ Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821 [TBL] [Abstract][Full Text] [Related]
24. Combined model-based and patient-specific dosimetry for Plyku D; Mena E; Rowe SP; Lodge MA; Szabo Z; Cho SY; Pomper MG; Sgouros G; Hobbs RF Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):989-998. PubMed ID: 29460025 [TBL] [Abstract][Full Text] [Related]
25. Utility of Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853 [TBL] [Abstract][Full Text] [Related]
26. Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept. Baum RP; Langbein T; Singh A; Shahinfar M; Schuchardt C; Volk GF; Kulkarni H Nucl Med Mol Imaging; 2018 Feb; 52(1):80-81. PubMed ID: 29391917 [TBL] [Abstract][Full Text] [Related]
27. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT. Baumann R; Koncz M; Luetzen U; Krause F; Dunst J Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556 [TBL] [Abstract][Full Text] [Related]
32. Detection and localisation of primary prostate cancer using Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639 [TBL] [Abstract][Full Text] [Related]
34. Spinal Tuberculosis Mimicking as Prostate Cancer Metastases in Ga-68 Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography. Gupta N; Elumalai RK; Verma R; Belho ES; Dhawan S Indian J Nucl Med; 2020; 35(3):271-273. PubMed ID: 33082696 [TBL] [Abstract][Full Text] [Related]
35. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122 [TBL] [Abstract][Full Text] [Related]
36. Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma - Is PSMA-PET-CT a helpful tool in radiation oncology? König L; Hauswald H; Flechtenmacher C; Heller M; Debus J; Haberkorn U; Kratochwil C; Giesel F Clin Transl Radiat Oncol; 2017 Dec; 7():79-82. PubMed ID: 29594233 [TBL] [Abstract][Full Text] [Related]
38. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre. Haran C; McBean R; Parsons R; Wong D J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933 [TBL] [Abstract][Full Text] [Related]
39. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Klein Nulent TJW; van Es RJJ; Krijger GC; de Bree R; Willems SM; de Keizer B Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1614-1621. PubMed ID: 28593386 [TBL] [Abstract][Full Text] [Related]
40. PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years. Shakespeare TP; Eggert E; Wood M; Westhuyzen J; Turnbull K; Rutherford N; Aherne N Radiother Oncol; 2019 Dec; 141():188-191. PubMed ID: 31668514 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]